SC
PRTK

Sculptor Capital’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Sculptor Capital’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-54,000
Closed -$277K – 284
2018
Q4 		$277K Buy
+54,000
New +$410K ﹤0.01% 208

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sculptor Capital's PRTK Position: Q1 2019 in Review

Sculptor Capital sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2019, closing a stake of 54,000 shares — an estimated $277K sold.

Sculptor Capital first reported a position in PRTK in Q4 2018 and held it in 1 quarter. The position peaked at $277K in Q4 2018. 94 funds tracked by Wall St. Rank hold PRTK as of Q1 2019.

  • Sculptor Capital reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Sculptor Capital sold 54,000 Paratek Pharmaceuticals, Inc. shares in Q1 2019, an estimated $277K.
  • Sculptor Capital first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2018 and held it in 1 quarter.
  • Sculptor Capital's Paratek Pharmaceuticals, Inc. position peaked at $277K in Q4 2018.
  • 94 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2019.

Based on Sculptor Capital's 13F filing for Q1 2019, filed 13 May 2019.